Danielle F Eytan1, Amanda L Blackford2, David W Eisele1, Carole Fakhry1. 1. 1 Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland, USA. 2. 2 Division of Oncology Biostatistics and Bioinformatics, Johns Hopkins University, Baltimore, Maryland, USA.
Abstract
OBJECTIVE: The aim of this study was to evaluate the prevalence of comorbidities among patients with head and neck squamous cell carcinoma (HNSCC) at the time of their cancer diagnosis and during their survivorship trajectory. The second aim was to evaluate the differences in comorbidities developed according to treatment type received. STUDY DESIGN: Retrospective cross-sectional. SETTING: SEER (Surveillance, Epidemiology, and End Results)-Medicare linked database. SUBJECTS AND METHODS: Individuals with a first-incident primary diagnosis of HNSCC from 2004 to 2011 per the SEER-Medicare database were included in analysis. The presence or absence of 30 comorbid conditions of interest was identified during distinct periods and analyzed according to treatment with surgery alone, primary (chemo)radiation, or surgery with (chemo)radiation. RESULTS: The study population consisted of 10,524 individuals diagnosed with HNSCC, with a mean age of 74.8 years. At diagnosis, hypertension, hyperlipidemia, chronic obstructive pulmonary disease, and diabetes were the most prevalent comorbidities, and they increased over time. The probability of developing treatment-related comorbidities such as pneumonia, dysphagia, weight loss, malnutrition, and dental issues rose significantly in the short and long term following treatment ( P < .05). By 5 years from cancer diagnosis, patients were most likely to have newly diagnosed hypertension, dysphagia, anemia, and weight loss. Primary surgery alone was associated with a lower risk of diagnosis with these treatment-related comorbidities, as compared with treatments involving radiation therapy and/or chemotherapy in the primary or adjuvant settings ( P < .05). CONCLUSIONS: There is a large burden of comorbidities among patients following HNSCC treatment, which warrant clinical attention during surveillance.
OBJECTIVE: The aim of this study was to evaluate the prevalence of comorbidities among patients with head and neck squamous cell carcinoma (HNSCC) at the time of their cancer diagnosis and during their survivorship trajectory. The second aim was to evaluate the differences in comorbidities developed according to treatment type received. STUDY DESIGN: Retrospective cross-sectional. SETTING: SEER (Surveillance, Epidemiology, and End Results)-Medicare linked database. SUBJECTS AND METHODS: Individuals with a first-incident primary diagnosis of HNSCC from 2004 to 2011 per the SEER-Medicare database were included in analysis. The presence or absence of 30 comorbid conditions of interest was identified during distinct periods and analyzed according to treatment with surgery alone, primary (chemo)radiation, or surgery with (chemo)radiation. RESULTS: The study population consisted of 10,524 individuals diagnosed with HNSCC, with a mean age of 74.8 years. At diagnosis, hypertension, hyperlipidemia, chronic obstructive pulmonary disease, and diabetes were the most prevalent comorbidities, and they increased over time. The probability of developing treatment-related comorbidities such as pneumonia, dysphagia, weight loss, malnutrition, and dental issues rose significantly in the short and long term following treatment ( P < .05). By 5 years from cancer diagnosis, patients were most likely to have newly diagnosed hypertension, dysphagia, anemia, and weight loss. Primary surgery alone was associated with a lower risk of diagnosis with these treatment-related comorbidities, as compared with treatments involving radiation therapy and/or chemotherapy in the primary or adjuvant settings ( P < .05). CONCLUSIONS: There is a large burden of comorbidities among patients following HNSCC treatment, which warrant clinical attention during surveillance.
Entities:
Keywords:
HNSCC; SEER; comorbidities; head and neck cancer
Authors: Amrita Mukherjee; Howard W Wiener; Russell L Griffin; Carrie Lenneman; Arka Chatterjee; Lisle M Nabell; Cora E Lewis; Sadeep Shrestha Journal: Head Neck Date: 2022-04-09 Impact factor: 3.821
Authors: A C H Willemsen; J H R J Degens; L W J Baijens; A-M C Dingemans; A Hoeben; F J P Hoebers; D K M De Ruysscher; A M W J Schols Journal: Front Nutr Date: 2020-11-26
Authors: Erik Haehl; Alexander Rühle; Simon Spohn; Tanja Sprave; Eleni Gkika; Constantinos Zamboglou; Anca-Ligia Grosu; Nils H Nicolay Journal: Front Oncol Date: 2022-01-03 Impact factor: 6.244
Authors: Melissa A Taylor; Jeffery Switchenko; William Stokes; Mihir R Patel; Mark McDonald; Conor Steuer; Ashley Aiken; Jonathan J Beitler; Dong M Shin; Nabil F Saba Journal: Cancer Med Date: 2021-07-20 Impact factor: 4.452